Bruker Launches Second-Generation FluoroType SARS-CoV-2 Plus PCR Test
|
By HospiMedica International staff writers Posted on 28 Jul 2020 |
|
Image: FluoroCycler® XT (Photo courtesy of Bruker Corporation)
Bruker Corporation (Billerica, MA, USA) has launched the FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay for the highly specific detection of the SARS-CoV-2 virus, which causes the respiratory and systemic disease COVID-19 (CV19).
The FluoroType SARS-CoV-2 plus assay is CE-IVD labelled according to the European IVD Directive (98/79/EC). In two clinical trials involving approximately 90 CV19 positive patients and over 100 CV19 negative individuals, the CV19 infection assay showed 100% sensitivity and 100% specificity. The FluoroType SARS-CoV-2 plus assay has been validated for respiratory samples (nasopharyngeal swabs and oropharyngeal swabs in viral transport medium) using commonly available laboratory real-time PCR thermocyclers. The kit includes all necessary reagents to produce up to 96 results in under two hours.
The FluoroType SARS-CoV-2 plus assay can also be used with Bruker´s FluoroCycler XT real-time PCR system or alternatively with other commonly available real-time thermocyclers. The assay targets two independent genes of the SARS-CoV-2 genome, while simultaneously allowing for the differentiation of non-SARS-CoV-2 patients by detecting four endemic human coronaviruses (HCoVs) using four different HCoV gene locations.
“With the combination of our GenoXtract (GXT) products for nucleic acid extraction, our latest FluoroCycler XT real-time thermocycler and dedicated detection assays, Bruker offers a complete solution for the sample preparation and detection of the SARS-CoV-2 virus,” said Dr. Wolfgang Pusch, Executive Vice President Microbiology & Diagnostics at Bruker Daltonics. “With the FluoroType SARS-CoV-2 plus assay we expand our portfolio by an assay with added value by detecting two gene targets. Additionally, the differentiation from other human coronaviruses, which for example can cause a common cold, reduces the risk of false positive results due to potential cross-reactivity. We expect that these analytical features enable a very robust second-generation PCR assay with highest sensitivity and specificity.”
Related Links:
Bruker Corporation
The FluoroType SARS-CoV-2 plus assay is CE-IVD labelled according to the European IVD Directive (98/79/EC). In two clinical trials involving approximately 90 CV19 positive patients and over 100 CV19 negative individuals, the CV19 infection assay showed 100% sensitivity and 100% specificity. The FluoroType SARS-CoV-2 plus assay has been validated for respiratory samples (nasopharyngeal swabs and oropharyngeal swabs in viral transport medium) using commonly available laboratory real-time PCR thermocyclers. The kit includes all necessary reagents to produce up to 96 results in under two hours.
The FluoroType SARS-CoV-2 plus assay can also be used with Bruker´s FluoroCycler XT real-time PCR system or alternatively with other commonly available real-time thermocyclers. The assay targets two independent genes of the SARS-CoV-2 genome, while simultaneously allowing for the differentiation of non-SARS-CoV-2 patients by detecting four endemic human coronaviruses (HCoVs) using four different HCoV gene locations.
“With the combination of our GenoXtract (GXT) products for nucleic acid extraction, our latest FluoroCycler XT real-time thermocycler and dedicated detection assays, Bruker offers a complete solution for the sample preparation and detection of the SARS-CoV-2 virus,” said Dr. Wolfgang Pusch, Executive Vice President Microbiology & Diagnostics at Bruker Daltonics. “With the FluoroType SARS-CoV-2 plus assay we expand our portfolio by an assay with added value by detecting two gene targets. Additionally, the differentiation from other human coronaviruses, which for example can cause a common cold, reduces the risk of false positive results due to potential cross-reactivity. We expect that these analytical features enable a very robust second-generation PCR assay with highest sensitivity and specificity.”
Related Links:
Bruker Corporation
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Mobile X-Ray System
K4W
Half Apron
Demi
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
Light-Based Technology to Measure Brain Blood Flow Could Diagnose Stroke and TBI
Monitoring blood flow in the brain is crucial for diagnosing and treating neurological conditions such as stroke, traumatic brain injury (TBI), and vascular dementia. However, current imaging methods like... Read more
AI Heart Attack Risk Assessment Tool Outperforms Existing Methods
For decades, doctors have relied on standardized scoring systems to assess patients with the most common type of heart attack—non-ST-elevation acute coronary syndrome (NSTE-ACS). The GRACE score, used... Read more
Surgical Techniques
view channel
Minimally Invasive Endoscopic Surgery Improves Severe Stroke Outcomes
Intracerebral hemorrhage, a type of stroke caused by bleeding deep within the brain, remains one of the most challenging neurological emergencies to treat. Accounting for about 15% of all strokes, it carries... Read more
Novel Glue Prevents Complications After Breast Cancer Surgery
Seroma and prolonged lymphorrhea are among the most common complications following axillary lymphadenectomy in breast cancer patients. These postoperative issues can delay recovery and postpone the start... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies
Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
B. Braun Acquires Digital Microsurgery Company True Digital Surgery
The high-end microsurgery market in neurosurgery, spine, and ENT is undergoing a significant transformation. Traditional analog microscopes are giving way to digital exoscopes, which provide improved visualization,... Read more
CMEF 2025 to Promote Holistic and High-Quality Development of Medical and Health Industry
The 92nd China International Medical Equipment Fair (CMEF 2025) Autumn Exhibition is scheduled to be held from September 26 to 29 at the China Import and Export Fair Complex (Canton Fair Complex) in Guangzhou.... Read more